In addition, the NLRP3 inhibitor MCC950 treatment reduced the development of liver fibrosis in CCl4-induced liver fibrosis mouse models, indicating that blocking NLRP3 inflammasome-dependent pyroptosis may be a promising therapeutic strategy. This evidence concerns the gene NLRP3 and Hepatic fibrosis.